March is Women's History Month. Let's celebrate the faces of all the women who make great things happen in the Tomaras Lab!
Duke’s long leadership in vaccine research and the Duke Human Vaccine Institute’s (DHVI) dogged 25-year pursuit of answers to HIV put the university and health system in an excellent position to ad
When the SARS-CoV-2 virus began a global pandemic, lives changed and were left in uncertainty. How can people combat a novel virus? Vaccines provide an answer.
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection
RTS,S/AS01 is an advanced pre-erythrocytic malaria vaccine candidate with demonstrated vaccine efficacy up to 86.7% in controlled human malaria infection (CHMI) studies; however, reproducible immun
Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS
The outcome of the recent Antibody Mediated Prevention (AMP) trials that tested infusion of the broadly neutralizing antibody (bnAb) VRC01 provides proof of concept for blocking infection from sens
Probiotic supplementation reduces inflammatory profiles but does not prevent oral immune perturbations during SIV infection
HIV/SIV infections lead to massive loss of mucosal CD4 + T cells and breakdown of the epithelial mucosa resulting in severe microbial dysbiosis and chronic immune activation that ultimately drive d